Skip to Content

Join the 'Xolair' group to help and get support from people like you.

Xolair News

New Hope for Kids With Multiple Food Allergies

Posted 12 Dec 2017 by Drugs.com

TUESDAY, Dec. 12, 2017 – A treatment for kids with more than one dangerous food allergy shows promise in early trials, researchers say. Almost one-third of people with a food allergy have reactions to more than one type of food. This can increase the risk of accidental exposure and life-threatening anaphylaxis, according to researchers at Stanford University School of Medicine. No treatment ...

FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children

Posted 8 Jul 2016 by Drugs.com

South San Francisco, CA – July 7, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) to treat moderate to severe persistent asthma in children six to 11 years of age who have had a positive skin test or in vitro reactivity to an airborne allergen and have symptoms that are ...

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the ...

FDA Medwatch Alert: Xolair (omalizumab): Drug Safety Communication - Slightly Elevated Risk of Cardiovascular and Cerebrovascular Serious Adverse Events

Posted 26 Sep 2014 by Drugs.com

ISSUE: An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug Xolair (omalizumab) than in those who were not treated with Xolair. As a result, FDA has added information about these potential risks to the drug label. The review found no difference in the rates of ...

Asthma Drug May Help Those With Chronic Hives

Posted 21 Jul 2014 by Drugs.com

MONDAY, July 21, 2014 – A drug already used to treat moderate-to-severe allergic asthma appears to offer relief to people with chronic hives who haven't been helped by standard medications, new research suggests. The prescription drug – omalizumab (Xolair) – is already available to treat hives, following U.S. Food and Drug Administration approval earlier this year for that use. The current ...

FDA Approves Xolair (omalizumab) for Chronic Idiopathic Urticaria

Posted 24 Mar 2014 by Drugs.com

South San Francisco, Calif. – March 21, 2014 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy5. Until ...

Options Increasing for Coping With Kids' Food Allergies

Posted 3 Aug 2012 by Drugs.com

FRIDAY, Aug. 3 – Kids with a serious food allergy generally have to steer clear of the offending food, but methods now under development could change that common scenario. More than 3 million American youths – about one of every 25 – have a food allergy of some sort, usually to milk, eggs or peanuts, according to U.S. government statistics. For them, "avoidance has been the mainstay of ...

Allergy Drug May Speed Up Kids' Ability to Tolerate Milk

Posted 22 Mar 2011 by Drugs.com

MONDAY, March 21 – Kids who are allergic to milk may be able to quickly develop tolerance by coupling the allergy medication Xolair with a gradual increase in their exposure to milk, known as sensitization, a new study suggests. An estimated 3 million children in the United States are allergic to some kind of food. Milk allergy is the most common food allergy among children, affecting about 2.5 ...

Xolair Reduces Seasonal Asthma Attacks for Inner City Kids: Study

Posted 16 Mar 2011 by Drugs.com

WEDNESDAY, March 16 – The injectable medication Xolair reduced asthma symptoms in inner city children with the respiratory condition, and almost eliminated seasonal peaks in asthma attacks, new research shows. When added to standard asthma treatments, Xolair (omalizumab) decreased the amount of inhaled steroid needed to maintain asthma control, according to the study, which is published in the ...

FDA Medwatch Alert: Xolair (omalizumab)

Posted 21 Feb 2007 by Drugs.com

Indications and Usage: for treatment of adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and ...

FDA Investigating Safety of Asthma Drug Xolair

Posted 16 Jul 2009 by Drugs.com

THURSDAY, July 16 – The U.S. Food and Drug Administration has begun a safety review of the asthma drug Xolair (omalizumab) after reports of an increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke, the agency said Thursday. Early results from the Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS) trial spurred ...

Ask a Question

Further Information

Related Condition Support Groups

Urticaria, Hives, Asthma - Maintenance

Xolair Patient Information at Drugs.com